Posaconazole
Systematic (IUPAC) name | |
---|---|
4-(4-(4-(4-(((3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-1,2,4-triazol-3-one
|
|
Clinical data | |
Trade names | Noxafil, Posanol |
AHFS/Drugs.com | monograph |
MedlinePlus | a607036 |
Licence data | EMA:Link, US FDA:link |
Pregnancy category |
|
Legal status |
|
Routes of administration |
Oral |
Pharmacokinetic data | |
Bioavailability | High |
Protein binding | 98 to 99% |
Metabolism | Hepatic glucuronidation |
Biological half-life | 16 to 31 hours |
Excretion | Fecal (77%) and renal (14%) |
Identifiers | |
CAS Number | 171228-49-2 |
ATC code | J02AC04 (WHO) |
PubChem | CID: 147912 |
DrugBank | DB01263 |
ChemSpider | 130409 |
UNII | 6TK1G07BHZ |
KEGG | D02555 |
ChEBI | CHEBI:64355 |
ChEMBL | CHEMBL1397 |
Synonyms | 4-{4-[4-(4-{[(5R)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one |
Chemical data | |
Formula | C37H42F2N8O4 |
Molecular mass | 700.778 g/mol |
|
|
|
|
(what is this?) (verify) |
Posaconazole is a triazole antifungal drug.[1][2] It marketed in the United States, the European Union, and in other countries by Schering-Plough under the trade name Noxafil. In Canada, posaconazole is marketed by Schering-Plough under the trade name Posanol.
Contents
Medical uses
It is used to treat invasive infections by Candida species, Mucor, and Aspergillus species in severely immunocompromised patients.[3][4]
Clinical evidence for its utility in treatment of invasive disease caused by Fusarium species (fusariosis) is limited.[5]
Pharmacology
Mode of action
Posaconazole works by disrupting the close packing of acyl chains of phospholipids, impairing the functions of certain membrane-bound enzyme systems such as ATPase and enzymes of the electron transport system, thus inhibiting growth of the fungi. It does this by blocking the synthesis of ergosterol by inhibiting of the enzyme lanosterol 14α-demethylase and accumulation of methylated sterol precursors. Posaconazole is significantly more potent at inhibiting 14-alpha demethylase than itraconazole.[6][7][8]
Microbiology
Posaconazole is active against the following microorganisms:[6][9]
- Candida spp.
- Aspergillus spp.
- Zygomycetes spp.
Pharmacokinetics
Posaconazole is absorbed within three to five hours. It is predominately eliminated through the liver, and has a half life of about 35 hours. Oral administration of posaconazole taken with a high-fat meal exceeds 90% bioavailability and increases the concentration by four times compared to fasting state.[9][10]
Research
There is also some indication that posaconazole may be the most effective treatment for both chronic and acute Chagas disease, showing much better efficacy than benznidazole.[11] Schering-Plough is currently recruiting participants for a phase 2 clinical trial in Argentina to test its efficacy against asymptomatic, chronic Chagas.[12]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found. – via JSTOR (subscription required)
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 6.0 6.1 Brunton L, Lazo J, Parker K. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. San Francisco: McGraw-Hill; 2006. ISBN 978-0-07-142280-2
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 9.0 9.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ "Am J Trop Med Hyg April 2010 vol. 82 no. 4"
- ↑ "A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267 AM1) (STOP CHAGAS)"